A Real-World Cost-Effectiveness Analysis of Rivaroxaban versus Vitamin K Antagonists for the Treatment of Symptomatic Venous Thromboembolism: Lessons from the REMOTEV Registry.

导出 OA

翻译打印收藏纠错

作者： Sabrina,Kepka ^[1] ; Elena-Mihaela,Cordeanu ^[2] ; Kevin,Zarca ^[3] ; Anne-Sophie,Frantz ^[4] ; Patrick,Ohlmann ^[5] ; Emmanuel,Andres ^[3] ; Pascal,Bilbault ^[6] ; Isabelle,Durand-Zaleski ^[7] ; Dominique,Stephan ^[1]

作者单位： Emergency Department, Strasbourg Regional University Hospital, 1 Place de l'Hôpital, 67091 Strasbourg, France. ^[1] ICube, UMR 7357, CNRS, 300 Bd Sébastien Brant, 67400 Illkirch-Graffenstaden, France. ^[2] Department of Hypertension, Vascular Disease and Clinical Pharmacology, Strasbourg Regional University Hospital, 67091 Strasbourg, France. ^[3] UMR 1260, INSERM Regenerative Nanomedecine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France. ^[4] URCEco, Hôtel Dieu, AP-HP, 1 Place du Parvis Notre Dame, 75004 Paris, France. ^[5] Cardiology Department, Strasbourg Regional University Hospital, 67091 Strasbourg, France. ^[6] Internal Medicine Department, Strasbourg Regional University Hospital, 67091 Strasbourg, France. ^[7] Translational Medicine Federation, University of Strasbourg, 67084 Strasbourg, France. ^[8] CRESS, INSERM, INRA , Université Paris-Est Créteil (UPEC), 94000 Créteil, France. ^[9]

关键词 cost-effectiveness direct oral anticoagulant pulmonary embolism rivaroxaban venous thromboembolism vitamin K antagonist